Circulating Serum Level of Visfatin in Patients with Endometrial Cancer

Table 4

Visfatin concentration in serum, depending on staging and grading group of endometrial cancer.

	Mean	Median	Min.	Max.	SD
Endometrioid/nonendometrioid	19.8/23.1	20.4/24.3	13.4/16.1	22.2/29.6	2.4/2.9	NS
G1/G2	17.3/22.2	18.3/23.9	13.2/10.2	19.9/31.3	1,8/3.7	0.03
G2/G3	22.2/31.8	23.9/33.8	10.2/14.6	31.3/41.2	3.7/4.2	0.002
FIGO I and II/FIGO III and IV	16.8/32.4	17.1/33.5	11.8/15.4	22.1/40.9	2.03/4.2	0.0002
Tumor size <2 cm or >2 cm	19.1/33.3	20.02/35.1	15.2/17.1	25.2/42.1	2.4/4.3	0.003
Infiltration of the myometrium: superficial/deep	18.4/30.6	19.1/31.8	11.2/17.3	25.1/38.7	2.2/3.6	0.004
Lymph vessels invasion +/−	25.5/22.3	27/23.1	17.2/16.5	29.1/26.6	2/2.2	NS
Vascular invasion +/−	29.8/21.4	30.3/22.3	16.7/19.1	39.2/30	4.1/2.8	0.02
Lymph nodes metastasis +/−	39.1/21.2	40.01/22.6	16.2/18.4	46.1/29.2	4.7/2.1	0.01